Zinger Key Points
- BioRestorative presents preliminary clinical data from its ongoing Phase 2 clinical trial of the company's lead clinical candidate.
- Data that was collected at weeks 26 and 52 post-injection demonstrates a positive trend compared to baseline.
- Get Monthly Picks of Market's Fastest Movers
BioRestorative Therapies, Inc. BRTX shares are trading higher Monday after the company presented preliminary clinical data from its ongoing Phase 2 clinical trial of the company’s lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease.
The Details:
BioRestorative Therapies presented the data at the Orthopaedic Research Society 2024 Annual Meeting on Sunday and hosted a webcast and slideshow to present the data to stakeholders on Monday morning before the market open.
BioRestorative said data that was collected at weeks 26 and 52 post-injection demonstrated a positive trend compared to baseline.
“We are thrilled with the progress of our ongoing clinical development programs. With regard to the Phase 2 study investigating the use of BRTX-100 in the treatment of cLDD, we are strongly encouraged by the preliminary data presented at ORS 2024. The preliminary clinical data shows meaningful signals in patients enrolled in the study and, importantly, no notable safety signals,” said Lance Alstodt, CEO of BioRestorative.
Related News: What’s Going On With Rivian Automotive Stock?
BRTX Price Action: According to Benzinga Pro, BioRestorative Therapies shares are up 7.86% at $3.02 at the time of publication.
Image: Raman Oza from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
